Literature DB >> 19050261

Binding of the long pentraxin PTX3 to factor H: interacting domains and function in the regulation of complement activation.

Livija Deban1, Hanna Jarva, Markus J Lehtinen, Barbara Bottazzi, Antonio Bastone, Andrea Doni, T Sakari Jokiranta, Alberto Mantovani, Seppo Meri.   

Abstract

The long pentraxin PTX3 is a multifunctional soluble molecule involved in inflammation and innate immunity. As an acute phase protein, PTX3 binds to the classical pathway complement protein C1q, limits tissue damage in inflammatory conditions by regulating apoptotic cell clearance, and plays a role in the phagocytosis of selected pathogens. This study was designed to investigate the interaction of PTX3 with factor H (FH), the main soluble alternative pathway regulatory protein. We report that PTX3 binds FH with an apparent K(d) of 1.1 x 10(-7) M, and define two binding sites for PTX3 on FH. The primary binding site is located on FH domains 19-20, which interact with the N-terminal domain of PTX3, while a secondary binding site on domain 7 binds the glycosylated PTX3 pentraxin domain. The FH Y402H polymorphism, which affects binding to the short pentraxin CRP, did not affect binding to PTX3. Surface-bound PTX3 enhances FH recruitment and iC3b deposition and PTX3-bound FH retains its activity as a cofactor for factor I-mediated C3b cleavage. Thus, our findings identify PTX3 as a unique FH ligand in that it can bind both of the two hot-spots of FH, namely SCR7 and SCR19-20 and indicate that PTX3 participates in the localization of functionally active FH.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19050261     DOI: 10.4049/jimmunol.181.12.8433

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  80 in total

Review 1.  Complement control protein factor H: the good, the bad, and the inadequate.

Authors:  Viviana P Ferreira; Michael K Pangburn; Claudio Cortés
Journal:  Mol Immunol       Date:  2010-08       Impact factor: 4.407

Review 2.  The impact of oxidative stress and inflammation on RPE degeneration in non-neovascular AMD.

Authors:  Sayantan Datta; Marisol Cano; Katayoon Ebrahimi; Lei Wang; James T Handa
Journal:  Prog Retin Eye Res       Date:  2017-03-20       Impact factor: 21.198

3.  Pentraxin-3 modulates lipopolysaccharide-induced inflammatory response and attenuates liver injury.

Authors:  Luis Perea; Mar Coll; Lucia Sanjurjo; Delia Blaya; Adil El Taghdouini; Daniel Rodrigo-Torres; José Altamirano; Isabel Graupera; Beatriz Aguilar-Bravo; Marta Llopis; Julia Vallverdú; Joan Caballeria; Leo A van Grunsven; Maria-Rosa Sarrias; Pere Ginès; Pau Sancho-Bru
Journal:  Hepatology       Date:  2017-07-18       Impact factor: 17.425

4.  The angiogenic inhibitor long pentraxin PTX3 forms an asymmetric octamer with two binding sites for FGF2.

Authors:  Antonio Inforzato; Clair Baldock; Thomas A Jowitt; David F Holmes; Ragnar Lindstedt; Marcella Marcellini; Vincenzo Rivieccio; David C Briggs; Karl E Kadler; Antonio Verdoliva; Barbara Bottazzi; Alberto Mantovani; Giovanni Salvatori; Anthony J Day
Journal:  J Biol Chem       Date:  2010-04-02       Impact factor: 5.157

5.  Role of the skin biopsy in the diagnosis of atypical hemolytic uremic syndrome.

Authors:  Cynthia M Magro; Shabnam Momtahen; Joseph Justin Mulvey; Aminah H Yassin; Robert B Kaplan; Jeffrey C Laurence
Journal:  Am J Dermatopathol       Date:  2015-05       Impact factor: 1.533

Review 6.  Biology of human pentraxin 3 (PTX3) in acute and chronic kidney disease.

Authors:  Marijn M Speeckaert; Reinhart Speeckaert; Juan J Carrero; Raymond Vanholder; Joris R Delanghe
Journal:  J Clin Immunol       Date:  2013-02-27       Impact factor: 8.317

Review 7.  Anti-complement-factor H-associated glomerulopathies.

Authors:  Marie-Agnes Dragon Durey; Aditi Sinha; Shambhuprasad Kotresh Togarsimalemath; Arvind Bagga
Journal:  Nat Rev Nephrol       Date:  2016-07-25       Impact factor: 28.314

8.  SARS-CoV-2 RNAemia and proteomic trajectories inform prognostication in COVID-19 patients admitted to intensive care.

Authors:  Clemens Gutmann; Kaloyan Takov; Sean A Burnap; Bhawana Singh; Hashim Ali; Konstantinos Theofilatos; Ella Reed; Maria Hasman; Adam Nabeebaccus; Matthew Fish; Mark Jw McPhail; Kevin O'Gallagher; Lukas E Schmidt; Christian Cassel; Marieke Rienks; Xiaoke Yin; Georg Auzinger; Salvatore Napoli; Salma F Mujib; Francesca Trovato; Barnaby Sanderson; Blair Merrick; Umar Niazi; Mansoor Saqi; Konstantina Dimitrakopoulou; Rafael Fernández-Leiro; Silke Braun; Romy Kronstein-Wiedemann; Katie J Doores; Jonathan D Edgeworth; Ajay M Shah; Stefan R Bornstein; Torsten Tonn; Adrian C Hayday; Mauro Giacca; Manu Shankar-Hari; Manuel Mayr
Journal:  Nat Commun       Date:  2021-06-07       Impact factor: 14.919

9.  Synergy between ficolin-2 and pentraxin 3 boosts innate immune recognition and complement deposition.

Authors:  Ying Jie Ma; Andrea Doni; Tina Hummelshøj; Christian Honoré; Antonio Bastone; Alberto Mantovani; Nicole M Thielens; Peter Garred
Journal:  J Biol Chem       Date:  2009-07-24       Impact factor: 5.157

10.  Characterization of pentraxin 3 in the horse and its expression in airways.

Authors:  Eve Ramery; Laurence Fievez; Audrey Fraipont; Fabrice Bureau; Pierre Lekeux
Journal:  Vet Res       Date:  2009-10-29       Impact factor: 3.683

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.